Sign in

CIK 0001649989

  • Non-accelerated filer
  • Smaller reporting company

Outlook Therapeutics, Inc.

Sign in to watch
Ticker
OTLK
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Sep 30
Incorporated
DE
Entity type
Operating
EIN
383982704
Phone
+1 609-619-3990
Business address
111 S. WOOD AVENUE, UNIT #100, ISELIN, NJ, 08830
Former names
Oncobiologics, Inc.
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$0
in 0 filings

Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Date Insider Transaction Shares Price Value Owned after
2024-03-20 Evanson Jeff CHIEF COMMERCIAL OFFICER Grant or award · Stock Option (Right to Buy) +25,000 25,000
2024-03-07 Evanson Jeff CHIEF COMMERCIAL OFFICER Purchase +62,484 $0.42 $26K 808,459
2023-04-17 Evanson Jeff Chief Commercial Officer Grant or award · Stock Option (Right to Buy) +192,143 192,143
2023-01-20 Evanson Jeff Chief Commercial Officer Sale −267,000 $1.11 $296K 745,975
2023-01-19 Evanson Jeff Chief Commercial Officer Sale −103,255 $1.22 $126K 1,012,975
2023-01-18 Evanson Jeff Chief Commercial Officer Sale −33,738 $1.25 $42K 1,116,230
2023-01-17 Evanson Jeff Chief Commercial Officer Sale −27,162 $1.31 $36K 1,149,968
2022-03-31 Evanson Jeff Chief Commercial Officer Grant or award · Stock Option (Right to Buy) +100,000 100,000
2021-12-21 Evanson Jeff Chief Commercial Officer Grant or award · Stock Option (Right to Buy) +800,000 800,000
2021-12-03 Evanson Jeff Chief Commercial Officer Purchase +35,200 $1.34 $47K 1,177,130
2021-02-23 Evanson Jeff Chief Commercial Officer Sale −8,554 $2.09 $18K 1,141,930
2021-02-12 Evanson Jeff Chief Commercial Officer Sale −56,973 $2.55 $145K 1,150,484
2020-03-19 Evanson Jeff Chief Commercial Officer Grant or award +1,207,457 1,207,457

Page 1 of 1 · 13 trades